A Phase 1/2 interventional study of INO-8875 and Placebo in Glaucoma and Ocular Hypertension, sponsored by Inotek Pharmaceuticals Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 77 Years. Per ClinicalTrials.gov, last updated 2012-10-15.
Sponsored by Inotek Pharmaceuticals Corporation · Phase 1/2, Interventional, and Treatment
The purpose of this study is to evaluate how tolerable, safe, and effective it is to give INO-8875 eye drops to adults with glaucoma or ocular hypertension.
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's enrollment of 144 is above the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →Inotek Pharmaceuticals Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Matched vehicle-control
Drug: Placebo
Adenosine agonist eye drop
Drug: INO-8875
eye drops for 14 days in one eye
Matched vehicle-control
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time frame: 14 days
Number of Participants with decreased Intra-ocular pressure
Time frame: 14 days
This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inotek Pharmaceuticals Corporation